User profiles for Brian Porter
 | Brian Porter-SzucsUniversity of Michigan Verified email at umich.edu Cited by 1481 |
[HTML][HTML] Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis
Background Secukinumab is an anti–interleukin-17A monoclonal antibody that has been
shown to control the symptoms of ankylosing spondylitis in a phase 2 trial. We conducted two …
shown to control the symptoms of ankylosing spondylitis in a phase 2 trial. We conducted two …
[BOOK][B] When nationalism began to hate: Imagining modern politics in nineteenth-century Poland
B Porter - 2000 - books.google.com
In When Nationalism Began to Hate, Brian Porter offers a challenging new explanation for
the emergence of xenophobic, authoritarian nationalism in Europe. He begins by examining …
the emergence of xenophobic, authoritarian nationalism in Europe. He begins by examining …
Predicting risk of hospitalization or death among patients receiving primary care in the Veterans Health Administration
L Wang, B Porter, C Maynard, G Evans, C Bryson… - Medical care, 2013 - journals.lww.com
Background: Statistical models that identify patients at elevated risk of death or hospitalization
have focused on population subsets, such as those with a specific clinical condition or …
have focused on population subsets, such as those with a specific clinical condition or …
Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective …
…, K Reich, AA Deodhar, IB McInnes, B Porter… - Annals of the …, 2019 - ard.bmj.com
Objectives Here, we present the reported incidence rates of inflammatory bowel disease (IBD)
in patients receiving treatment with secukinumab for psoriasis (PsO), psoriatic arthritis (…
in patients receiving treatment with secukinumab for psoriasis (PsO), psoriatic arthritis (…
[HTML][HTML] Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3
…, L Pricop, M Andersson, A Readie, B Porter - Arthritis research & …, 2017 - Springer
Background Secukinumab, an anti–interleukin-17A monoclonal antibody, improved the
signs and symptoms of ankylosing spondylitis (AS) in two phase 3 studies (MEASURE 1 and …
signs and symptoms of ankylosing spondylitis (AS) in two phase 3 studies (MEASURE 1 and …
Elevated frequencies of highly activated CD4+ T cells in HIV+ patients developing immune reconstitution inflammatory syndrome
…, Y Mahnke, JN Hodge, BO Porter… - Blood, The Journal …, 2010 - ashpublications.org
Immune reconstitution inflammatory syndrome (IRIS) is a considerable problem in the treatment
of HIV-infected patients. To identify immunologic correlates of IRIS, we characterized T-…
of HIV-infected patients. To identify immunologic correlates of IRIS, we characterized T-…
Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study
…, T Jui-Cheng, M Andersson, B Porter… - Annals of the …, 2017 - ard.bmj.com
Background There is significant unmet need in patients with ankylosing spondylitis (AS)
who have inadequate response or intolerance to anti-tumour necrosis factor (TNF) treatment. …
who have inadequate response or intolerance to anti-tumour necrosis factor (TNF) treatment. …
Genetic tuning of digital PID controllers
B Porter, AH Jones - Electronics letters, 1992 - infona.pl
The techniques of genetic algorithms are proposed as an alternative means of tuning digital
PID controllers. This use of genetic algorithms is particularly attractive because the same …
PID controllers. This use of genetic algorithms is particularly attractive because the same …
[BOOK][B] Primary care: Art and science of advanced practice nursing
LM Dunphy, J Winland-Brown, B Porter, D Thomas - 2015 - books.google.com
… Porter do not represent official views of Novartis, the VA, the FDA, the NIH, or any other US
… Brian O. Porter again has provided a thoughtful and in-depth update on the pathophysiology …
… Brian O. Porter again has provided a thoughtful and in-depth update on the pathophysiology …
Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study
…, P Emery, EM Delicha, Z Talloczy, B Porter - …, 2019 - academic.oup.com
Objective To evaluate the effect of secukinumab, a fully human anti-interleukin-17A monoclonal
antibody, on efficacy, imaging outcomes, and safety through 4 years (208 weeks) in …
antibody, on efficacy, imaging outcomes, and safety through 4 years (208 weeks) in …